Latest Conference Articles

Ashley Marenyi, RN, BSN, OCN, highlights the importance of counseling patients with head and neck cancer on the short-term and long-term adverse effects of radiation treatment.

Specialists highlight the best practices and latest treatment regimens for patients presenting with myelofibrosis, polycythemia vera, and essential thrombocythemia.

Combined adjuvant treatment with mRNA-4157 in combination with pembrolizumab improved recurrence rates in patients with resected high-risk melanoma.

Patients who received pembrolizumab plus cisplatin and gemcitabine achieved a median overall survival of 12.7 months, compared with 10.9 months with cisplatin and gemcitabine alone.

A genome-wide methylome enrichment platform may help identify multiple early-stage cancers.

The pathologic complete response rate with durvalumab was 17.2% vs 4.3% with placebo, reflecting an absolute difference of 12.9%.

Findings from the TAPESTRY trial showed that approximately 40% of patients with genetic conditions may be missed by current NCCN guidelines.

Combined adjuvant treatment with atezolizumab and bevacizumab was determined to deliver a statistically significant recurrence-free survival benefit to patients with resected hepatocellular carcinoma.

Meghan K. Berkenstock, MD, discusses the growing need for strong collaboration between ophthalmologists and gynecologic oncology care teams.

Pembrolizumab inspired a 70% risk reduction in women with mismatch repair–deficient advanced endometrial cancer and a 46% risk reduction in patients with mismatch repair–proficient disease.

Mary Katherine Montes de Oca, MD, discusses the potential benefit of cryocompression therapy in preventing peripheral neuropathy in patients with gynecologic cancers who are receiving chemotherapy.

Lindsay Diamond, MSN, AGNP-C, AOCNP, discusses findings from CheckMate 274 and other data presented during the 2023 ASCO Genitourinary Cancers Symposium.

Patients with ovarian cancer who received hyperthermic intraperitoneal chemotherapy with cytoreductive surgery did not experience worse health-related quality of life, according to investigators.

Arash Rezazadeh Kalebasty, MD, discusses the rates of dose reduction and treatment discontinuation for patients with hormone-sensitive prostate cancer receiving combination therapy with darolutamide.

In the all-comer population, the overall response rate was 33.8%, including a complete response rate of 7.5% and a partial response rate of 26.3%.

Research presented at the 2023 Society of Gynecologic Oncology Annual Meeting On Women’s Health suggests that the Carolina frailty index score may be useful for women with ovarian cancer.

The gynecological cancer lymphedema questionnaire and the lower extremity lymphedema screening questionnaire showed a demonstrable correlation in total scores, according to an analysis of women with advanced endometrial cancer.

Terri Pollack, DNP, APRN, FNP-C, PMHNP-BC, discusses key data that may affect clinical practice for nurses from the 2023 GI Cancers Symposium.

In this episode of "The Vitals," Terri Pollack, DNP, APRN, FNP-C, PMHNP-BC, underscores potentially practice-changing data which were presented during the 2023 GI Cancers Symposium.

Nivolumab/Cabozantinib continued to outperform sunitinib in an updated analysis of the phase 3 CheckMate 9ER trial.

Karyn A. Goodman, MD, MS, provides perspective on the potential advantages of stereotactic body radiation therapy in locally advanced pancreatic cancer.

Patients with papillary high-risk non-muscle-invasive bladder cancer whose disease was BCG-unresponsive showed continued antitumor activity with pembrolizumab monotherapy.

Terri Pollack, DNP, APRN, FNP-C, PMHNP-BC, shares some of her top takeaways from the 2023 ASCO GI Cancers Symposium.

Extended follow-up of the CheckMate 274 trial showed continued efficacy with nivolumab in patients with muscle-invasive urothelial cancer who had undergone radical resection.

Real-world data support front-line maintenance with avelumab for patients with locally advanced or metastatic urothelial carcinoma following platinum-based chemotherapy.

The median overall survival was 42.1 months with abiraterone plus olaparib and 34.7 months with abiraterone plus placebo in patients with metastatic castration-resistant prostate cancer.

Approximately 30% of patients remained on treatment with darolutamide for over 4 years, according to a long-term safety and tolerability updated from the ARAMIS rollover study.

At a median follow-up of 24.9 months, imaging-based progression-free survival was not reached among patients with metastatic castration-resistant prostate cancer who had received talazoparib plus enzalutamide.

Long-term data support a de-escalated dose of tamoxifen for certain women with breast intraepithelial neoplasia who are unable to receive the standard dose.

Patients with RAS-wild-type metastatic colorectal cancer did not experience a benefit in terms of response rate or survival when cetuximab was added to the first cycle of chemotherapy.